blockchain currencies- Top Knowledge

Huitai Medical: Using raised funds and self-owned funds to increase capital of 700 million yuan to wholly-owned subsidiaries. Huitai Medical announced that the company held the 20th meeting of the second board of directors and the 17th meeting of the second board of supervisors on December 12, 2024, and reviewed and approved the Proposal on Using raised funds and self-owned funds to increase capital to wholly-owned subsidiaries. The company agreed to increase its capital by 700 million yuan to Shanghai Hongtong Industrial Co., Ltd., a wholly-owned subsidiary, of which 438 million yuan of interest-bearing loans provided to Shanghai Hongtong with raised funds were converted into capital increase, and 262 million yuan was increased with its own funds. After the capital increase is completed, the registered capital of Shanghai Hongtong will increase from RMB 18,489,300 to RMB 26,548,200, and it will remain a wholly-owned subsidiary of the company.Xinxiangwei: Shareholder Xinyu Yijiade intends to reduce its shareholding by no more than 1%. Xinxiangwei announced that as of the disclosure date, Shareholder Xinyu Yijiade holds 20,175,800 shares of the company, accounting for 4.39% of the company's total share capital. Xinyu Yijiade plans to reduce the number of shares of the company by no more than 4,595,300 shares through centralized bidding or block trading of Shanghai Stock Exchange within 90 days after 15 trading days from the date of announcement, and the proportion of reduced shares in the company's total share capital is no more than 1%.Market News: The United Arab Emirates will restrict oil transportation in the case of OPEC+promoting compliance with quotas.

Market News: Trump's assistant asked Trump if it was possible to abolish the Federal Deposit Insurance Corporation (FDIC).Haitian Weiye, a soy sauce manufacturer, is reported to have hired a bank to handle the listing in Hong Kong. According to informed sources, Haitian Weiye, one of the largest condiment manufacturers in China, has hired CICC, Goldman Sachs and Morgan Stanley to handle the second listing in Hong Kong, which may raise at least $1.5 billion. According to people familiar with the matter, Haitian plans to submit a preliminary prospectus to the Hong Kong Stock Exchange as early as January.Contemporary Amperex Technology Co., Limited traded 175,000 shares today with a turnover of 44,625,200 yuan, while Contemporary Amperex Technology Co., Limited traded 175,000 shares today with a turnover of 44,625,200 yuan, accounting for 0.58% of the total turnover of the day. The average transaction price was 255 yuan, which was 4.51% lower than the market closing price of 267.03 yuan, of which the highest transaction price was 267.03 yuan and the lowest transaction price was 218.97 yuan.

Navigation warning to carry out military missions in the northern Bohai Sea. According to the website of China Maritime Safety Administration, Huludao Maritime Safety Administration issued a navigation warning. From 6: 00 to 16: 00 on December 14, military exercises were held in parts of the northern Bohai Sea, and it was forbidden to enter.Huawang Technology: Zhang Yancheng, the director, plans to reduce the company's shares by no more than 0.3443%. Huawang Technology announced that Zhang Yancheng, the company's director and senior manager, plans to reduce the company's shares by no more than 1.6 million shares through centralized bidding on the Shanghai Stock Exchange within three months after the announcement date, accounting for 0.3443% of the company's total share capital. The reduction price will be determined according to the market price. Zhang Yancheng currently holds 6,671,700 shares of the company, accounting for 1.4357% of the company's total share capital.Huabei Pharmaceutical Co., Ltd.: Four kinds of drugs under the company are planned to be selected for national centralized drug procurement. Huabei Pharmaceutical announced that the company and its subsidiary Xiantai Company participated in the tenth batch of national centralized drug procurement, and all four varieties are planned to be selected, including penicillin sodium for injection, piperacillin sodium for injection, ampicillin sodium for injection and sulbactam sodium for injection. The price of the drug to be selected this time has decreased compared with the original sales price. In 2023, the sales income of penicillin sodium for injection was 129 million yuan, accounting for 1.28% of the annual operating income. If the bid is confirmed and the purchase and sale contract is signed, the company will fully guarantee the supply according to the demand of the selected area, and promote the increment of related products in the selected area and the development of the off-standard market.